Pitfalls and caveats in BRCA sequencing

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Hereditary breast cancer accounts for 5-10% of all cases.
• Germline mutations in BRCA1 and BRCA2 genes significantly increase breast and ovarian cancer risk.
• Direct nucleotide sequencing is the gold standard for detecting mutations in BRCA1 and BRCA2.

Purpose of the Study:

• To discuss the challenges in detecting hereditary breast cancer-associated mutations.
• To explore reasons for negative BRCA1/BRCA2 mutation detection in hereditary cancer families.
• To highlight the potential role of other genes in hereditary breast cancer predisposition.

Main Methods:

• Review of mutation detection techniques for BRCA1 and BRCA2.
• Discussion of mutation types: frameshift, nonsense, and missense.
• Analysis of factors contributing to false-negative results in genetic testing.

Main Results:

• Missense mutations can be difficult to interpret clinically.
• BRCA1/BRCA2 mutations are identified in only 30-70% of families with suspected hereditary cancer.
• Negative results may stem from mutations in regulatory regions, epigenetic silencing, large genomic rearrangements, or mutations in other genes.

Conclusions:

• Negative BRCA1/BRCA2 testing does not rule out a hereditary predisposition.
• Mutations in undiscovered genes or interacting low-penetrance genes, such as CHEK2, are potential explanations.
• Comprehensive genetic evaluation is crucial for understanding hereditary cancer risk.